Do you want to know how silent your AAV capsid transfer is?
In the field of gene therapy, the ability of Adeno-associated virus (AAVs) vectors to deliver therapeutic genes without detection by the immune system is key.
Nevertheless, the presence of Neutralizing Antibodies (NAbs) can create immune barriers, which can hinder the efficacy of AAV-based therapy. Therefore, detecting NAbs is essential to overcome roadblocks in the development of AAV-based human gene therapies.
Assessing the "silence” of an AAV capsid is critical for the development of effective gene therapies.
That's why we are excited to introduce our unique iLite® AAV NAb platform for different AAV serotypes!